Funding for this research was provided by:
University of Auckland (NA)
Received: 15 October 2018
Accepted: 24 June 2019
First Online: 9 July 2019
Ethics approval and consent to participate
: The trial was approved by the New Zealand Ministry of Health ethics committee (NTY/09/01/002) and all patients provided written informed consent.
: Not applicable.
: Nicola Dalbeth reports research grant funding from Amgen and AstraZeneca/Ironwood, speaker fees from Pfizer, Janssen, and Abbvie, and consulting fees from Horizon and Kowa. Kate Palmano was previously employed by Fonterra Co-operative Group Ltd. The other authors declare no conflicts of interest.